Cytokinetics Remains Positive on Negative Phase II Reldesemtiv Study in ALS – MedCityNews

Read article - Quotes Elijah Stommel, professor of neurology, about data presented by drugmaker Cytokinetics from the Phase II FORTITUDE-ALS study of reldesemtiv in ALS at the American Academy of Neurology's annual meeting in Philadelphia. Despite the trial not showing statistical significance on the primary or secondary efficacy endpoints in Phase II, the company views the data as supportive of reldesemtiv's Phase III development. "Of course, the company is interested in making money," said Stommel, who was not involved with the study. "Remember when a large Phase III trial is done, it prevents those ALS patients from participating in another trial that might have more efficacy."